Please login to the form below
quarterly sales
This page shows the latest quarterly sales news and features for those working in and with pharma, biotech and healthcare.
Novartis stumbles in Q2 as COVID-19 impacts sales
Net profit drops by 4% as pandemic hits sales. Swiss pharma company Novartis has reported a drop in its quarterly sales and profit as the COVID-19 pandemic impacts its 2020 ... Net sales in the quarter from continuing operations declined by 1% to $11.3bn
Latest news
-
Biogen files Tecfidera follow-up in the US
The tolerability issue hasn’t held back Tecfidera commercially, however, with quarterly sales currently running at more than $1bn, despite tougher competition overall in the MS market.
-
Generic threat looms to J&J’s blockbuster Zytiga in US
launches. The importance of Zytiga to J&J at the moment can’t really be overstated: its quarterly sales are nearly $1bn – well over half from the US – and growing at ... Zytiga will enter the market and will result in a significant decline in
-
AZ agrees to $320m deal for Zoladex
products. The deal, which is expected to close by the end of March, will see AZ receive a $250m upfront payment for the rights, with double-digit quarterly sales-based payments ... ongoing. A further $70m is also up for grabs should Zoladex (goserelin
-
GSK's Witty ends on a high, but warns 2017 looking 'uncertain'
Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline. ... Other generics from Mylan and Hikma are under regulatory review, however, which could be directly substitutable and accelerate the decline in the brand's
-
2017 set to be a "defining year" for AZ
The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer Crestor (rosuvastatin) - saw sales cut in half in the fourth quarter after the loss of US patent protection, with ... The decline was, however, offset by good growth for non-small
More from news
Approximately 9 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
How my grandmother prompted a crisis of creativity in healthcare advertising
That’s the kind of creativity that builds a brand, not just quarterly sales figures.
-
20 for 2020 – Five pharma companies to watch
At the moment Humira accounts for nearly two-thirds of AbbVie’s total sales. ... The merger was completed shortly after BMS reported the first decline in quarterly sales of its immuno-oncology blockbuster Opdivo (nivolumab) since its launch five years
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Page & Page and Partners
Page & Page is an independent creative agency on a mission to close the healthcare gap through the power of...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
